Through the World Health Organization Global Benchmarking Tool (#GBT), several countries have now reached Maturity Level 3 (#ML3),a milestone that signals a stable, well-functioning regulatory system capable of protecting public health.
Countries like #Ghana, #Tanzania, #Nigeria, #Rwanda, #Senegal, #South_Africa, #Egypt, #Zimbabwe, and #Ethiopia have all made significant progress toward or achieved ML3 status.
𝐒𝐨 𝐰𝐡𝐚𝐭 𝐝𝐨𝐞𝐬 𝐭𝐡𝐢𝐬 𝐫𝐞𝐚𝐥𝐥𝐲 𝐦𝐞𝐚𝐧?
It means these authorities are no longer operating reactively.
They are moving toward risk-based, data-driven oversight of their pharmaceutical markets.
As countries reach ML3, track & trace initiatives start to emerge or accelerate.
𝐖𝐡𝐲?
Because at this level, regulators are expected to:
=Strengthen market surveillance
=Enable targeted recalls
=Improve supply chain visibility
=Act quickly against substandard and falsified medicines
In other words, controlling the market requires more than regulations,it requires end-to-end visibility.
This explains the recent wave of announcements regarding track and trace from middle of 2025 around pharmaceutical traceability systems across the region.
The real shift is From fragmented oversight to real-time control of the supply chain, and that’s a game changer for patient safety, market integrity, and trust.
Pic from World Health Organization